Almac's North Carolina Facility Doubles Capacity
Almac’s North Carolina Facility Doubles Capacity
Almac Clinical Services' site in Durham, N.C., recently doubled its capacity and is a licensed pharmacy. In addition, it successfully passed an FDA inspection earlier this year. The Durham facility was part of the Duke Clinical Research Institute from 1990 to 2000 and provided clinical pharmacy, packaging, distribution and supply chain services, which it continues to do as Almac. The division has seen continued growth from clients operating in the not- for-profit sector on academically based clinical trials.
The unit's staff is experienced with the academically-based trials and has understanding of the full clinical trial process, including disease state knowledge, how patients move through the hospital and pharmacy best practice when working directly with investigators. Project leaders are also involved with writing the CTM section of the clinical protocol through to reconciling drug returned from the clinical sites at close out.
Donna Christopher, VP of Operations at Almac Clinical Services, Durham Facility commented, "As our business continues to evolve under the Almac brand we have stayed close to our roots in academically based clinical trials - an area where our expertise lies. Alongside our core contract services, we also advise many of our clients on how to conduct their trials. From the outset we provide information on clinical input, study materials required, efficient drug kits design as well as full supply chain management in addition to providing training and monitoring to sites. We work together with our Academic clients to ensure their clinical trials are run to maximum efficiency enabling them to focus solely on their trial results. In recent months we have doubled our capacity to enable us to meet the increased demands for our services.”
If you would like more information on the services we provide or are an Academic Institution looking for a partner to manage your clinical trial please visit: http://www.almacgroup.com/clinicalservices/academic-clinical-trials.aspx
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
